<DOC>
	<DOCNO>NCT02874768</DOCNO>
	<brief_summary>This single-blind randomized clinical trial . Patients undergo abdominal surgery enrol randomly divide two group : dexmedetomidine group propofol group . In dexmedetomidine group , patient receive continuous intravenous infusion dexmedetomidine ( infusion dosage range : 0.1 ~ 0.7 mcg/kg/h ) . In propofol group , patient receive continuous intravenous infusion propofol ( infusion dosage range : 0.3 ~ 1.6 mg/kg/h ) . Hemodynamics continuously monitor use non-invasive monitoring chest bioreactance technique preset time point ( 0 , 2 , 4 , 6 , 12h 24h ) . Clinical data vital sign , hemodynamic parameter , laboratory result fluid balance record . The microcirculation examine Cytocam . The following microcirculatory parameter investigate : total small vessel density , perfuse small vessel density , microvascular flow index , heterogeneity index . The enzyme-linked immunosorbent assay use measure serum level endocan , diamine oxidase , neutrophil gelatinase-associated lipocalin preset time point . The primary goal study compare effect microcirculation dexmedetomidine propofol intensive care unit patient abdominal surgery .</brief_summary>
	<brief_title>Comparison Between Dexmedetomidine Propofol Patients Intensive Care Unit After Abdominal Surgery</brief_title>
	<detailed_description />
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>nonemergent major abdominal surgery ICU admission need sedation ICU stay age young 20 year old 89 year refractory bradycardia ( HR &lt; 60 bpm treatment ) severe AV block ( 2nd 3rd degree ) refractory shock ( MAP &lt; 60 mm Hg treatment ) severe heart failure NYHA 4 new onset myocardial infarction within 4 week receive CPR within 4 week APACHE score &gt; 30 enrollment severe liver cirrhosis CHILD B C pregnancy allergic history dexmedetomidine propofol enrol clinical trial related dexmedetomidine propofol within 4 week nonnative speaker</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>